Drug intelligence / Profile preview

Riva Pol theta inhibitor

Development stage: Preclinical
Lead developer: Riva
Modality: Small Molecules

Overview

Riva Therapeutics is developing a small molecule inhibitor program targeting DNA polymerase theta (Polθ, also known as POLQ). Polθ is a specialized DNA polymerase that plays a central role in the microhomology-mediated end joining (MMEJ) DNA repair pathway. This pathway is often utilized by cancer cells that are deficient in homologous recombination (HR), such as those with BRCA1 or BRCA2 mutations. Inhibition of Polθ in these HR-deficient cells leads to genomic instability and cell death through a synthetic lethal mechanism. The program is currently in the preclinical stage, aimed at treating various HR-deficient solid tumors, including breast, ovarian, and prostate cancers.

Other names: Pol theta inhibitor programPolθ inhibitor programPOLQ inhibitor program

Targets

POLQ (DNA polymerase theta)

Beyond the preview

Go deeper on Riva Pol theta inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Riva Pol theta inhibitor.

Explore the full profile